Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Short Interest Update

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM - Get Free Report) was the recipient of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 1,980,000 shares, a drop of 9.6% from the March 31st total of 2,190,000 shares. Based on an average daily volume of 354,100 shares, the short-interest ratio is presently 5.6 days.

Analyst Upgrades and Downgrades

Several research analysts have commented on ATNM shares. Cantor Fitzgerald reiterated an "overweight" rating and set a $21.00 price target on shares of Actinium Pharmaceuticals in a report on Monday, April 1st. StockNews.com raised Actinium Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Monday. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Actinium Pharmaceuticals in a report on Monday. Finally, Maxim Group upped their price objective on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a "buy" rating in a research report on Tuesday, March 19th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $25.72.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ATNM. Creative Financial Designs Inc. ADV grew its holdings in shares of Actinium Pharmaceuticals by 19.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company's stock worth $101,000 after purchasing an additional 3,175 shares during the period. Sanders Morris Harris LLC purchased a new stake in Actinium Pharmaceuticals during the first quarter worth approximately $78,000. Finally, Brandywine Global Investment Management LLC acquired a new stake in shares of Actinium Pharmaceuticals in the third quarter worth $1,033,000. Institutional investors and hedge funds own 27.50% of the company's stock.

Actinium Pharmaceuticals Stock Performance

Actinium Pharmaceuticals stock traded up $0.56 during trading hours on Monday, hitting $7.43. The stock had a trading volume of 244,842 shares, compared to its average volume of 322,240. Actinium Pharmaceuticals has a 1-year low of $4.00 and a 1-year high of $9.86. The firm has a market capitalization of $218.44 million, a price-to-earnings ratio of -4.06 and a beta of 0.01.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM - Get Free Report) last announced its earnings results on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.21. The business had revenue of $0.08 million for the quarter. As a group, sell-side analysts forecast that Actinium Pharmaceuticals will post -1.87 EPS for the current fiscal year.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.